4th Quarter - Report

THE RUSSELL GROUP, INC. for GENERIC PHARMACEUTICAL ASSOCIATION

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 515, H.R. 1260, Patent Reform Act of 2009 - Issues relative to patent quality

LobbyistCovered position, as disclosed
EDWARD BARRON —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE; Federal Trade Commission (FTC); Office of Management & Budget (OMB)

Bills named: H.R. 1260 (111th), S. 515 (111th)

Pharmacy PHA

Issues relative to generic pharmaceuticals and generic biologics; FY 2011 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill (Title VI - Related Agencies and Food and Drug Administration Department of Health and Human Services); funding FDA Office of Generic Drugs; H.R. 1427, S. 726 - Promoting Innovation and Access to Life-Saving Medicine Act (entire bill); S. 369 - Preserve Access to Affordable Generics Act (entire bill)

LobbyistCovered position, as disclosed
EDWARD BARRON —
TYSON REDPATH —
RANDALL RUSSELL —

Contacted: Federal Trade Commission (FTC); SENATE; Office of Management & Budget (OMB); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: S. 369 (111th), H.R. 1427 (111th), S. 726 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.